þ -dependent isocitrate dehydrogenase genes 1 and 2 (IDH1 and IDH2) have recently been found in adult acute myeloid leukemia (AML) patients with a prevalence rising up to 33%. To investigate the frequency of IDH1/2 mutations in pediatric AML, we characterized the mutational hotspot (exon 4) of these genes in diagnostic samples from 460 pediatric AML patients. Our analysis identified somatic IDH1/2 mutations in 4% of cases (IDH1 R132 n ¼ 8; IDH2 R140 n ¼ 10) and the minor allele of single-nucleotide polymorphism (SNP) rs11554137 in 47 children (10.2%). IDH mutations were associated with an intermediate age (P ¼ 0.008), FAB M1/M2 (P ¼ 0.013) and nucleophosmin1 mutations (P ¼ 0.001). In univariate analysis, IDH mutated compared with IDH wildtype patients showed a significantly improved overall survival (OS; P ¼ 0.032) but not event-free survival (EFS; P ¼ 0.14). However, multivariate analysis did not show independent prognostic significance. Children with at least one minor allele of IDH1 SNP rs11554137 had similar EFS (P ¼ 0.27) and OS (P ¼ 0.62) compared with major allele patients. Gene expression profiles of 12 IDH mutated were compared with 201 IDH wildtype patients to identify differentially expressed genes and pathways. Although only a small number of discriminating genes were identified, analysis revealed a deregulated tryptophan metabolism, and a significant downregulation of KYNU expression in IDH mutated cases.
Introduction
Although treatment results in childhood acute myeloid leukemia (AML) have improved during the last 30 years, there is still a significant number of patients with dismal prognosis. [1] [2] [3] To date, analysis of cytogenetic aberrations provide the most important prognostic information at diagnosis of this heterogeneous disease. 4, 5 Furthermore, different mutations have been identified in several genes in childhood AML, including FLT3, 6 NPM1 (nucleophosmin1), 7 CEBPA 8,9 and WT1. 10, 11 Some of these genetic alterations have been associated with treatment outcome and may serve as a basis for better risk assessment and molecularly based therapies.
Recently, by sequencing an AML genome, a somatic mutation was found in codon 132 of the gene for isocitrate dehydrogenase 1 (IDH1). 12 The protein encoded by this gene is found in the cytoplasm and peroxisomes. It is an NADP þ -dependent isocitrate dehydrogenase and has a significant role in cytoplasmic NADPH production. The same codon of IDH1 is frequently affected by mutations in malignant glioblastomas. 13 IDH2 has the same enzymatic activity as IDH1 but is located in the mitochondrial matrix. IDH2 mutations were reported in codons R140 and R172 in AML. 14 Mutations of both IDH1 and IDH2 provide a new ability to the enzyme to catalyse the NADPH-dependent reduction of alpha-ketoglutarate to 2-hydroxyglutarate. Excess accumulation of oncometabolite 2-hydroxyglutarate lead to DNA damage mediated by elevated levels of reactive oxygen species. 14, 15 In addition, mutant IDH appears to affect TET2 activity and thereby it induces changes in global and genespecific gene methylation. 16 Discovery of IDH mutations led to renewed efforts to decipher the role of altered metabolic processes in cancer. 17 Several studies confirmed the high prevalence of IDH1 and also IDH2 mutations in adult AML. [18] [19] [20] [21] [22] [23] The prognostic importance of IDH mutations has been contradictive in these studies. Furthermore, a single-nucleotide polymorphism (SNP) in exon 4 of the IDH1 gene has been reported to be associated with poor prognosis in adult cytogenetically normal AML. 24 In contrast to adult AML, only a few reports concerning genetic aberrations of the IDH genes have been published in childhood AML. Although in a series of 257 children no IDH1 mutation was detected, 25 IDH1 mutations were identified in 4 out of 165 pediatric AML patients in an Italian study. 26 To the best of our knowledge one single case of an 12-year-old boy with an IDH2 mutation 27 but no studies on the IDH1 SNP rs11554137 in childhood AML have been reported to date.
Therefore, we performed an analysis of IDH1/2 mutations and the IDH1 SNP rs11554137 in 460 childhood AML patients. All patients were intensively treated within consecutive multicenter trials of the AML-BFM (Berlin-Frankfurt-Mü nster) and DCOG study groups.
Patients and methods

Patients
Bone marrow or peripheral blood samples from initial diagnosis were obtained from 460 patients younger than 18 years with AML (French-American-British (FAB) classification M0-M7). A total of 335 patients were treated uniformly within the two Figure S2) . 1, 28, 29 The other 125 children with AML were treated between 1987 and 2005 according to consecutive DCOG treatment protocols. Details of these treatment protocols have been published previously; treatment consisted of four to five blocks of intensive chemotherapy, using a standard cytarabine and anthracycline backbone. [30] [31] [32] Stem cell transplantation in CR1 was used only in selected high-risk patients. The study was approved by the local research ethics committees. Written informed consent from patients, parents or guardians was obtained. The median follow-up time for patients under follow-up was 2.4 years (range: 0.2-10 years).
Cytogenetic analyses
Cytogenetic analyses were carried out and centrally reviewed using standard chromosome-banding analysis, and using reverse transcription (RT)-PCR and/or fluorescent in-situ hybridization for recurrent non-random genetic abnormalities, including t(15;17), inv(16), t(8;21) and MLL-gene rearrangements as reported previously. 1, 5 Mutational analysis of IDH1 and IDH2
Preparation of mononuclear cells and extraction of genomic DNA were performed as reported previously. 7, 10, 24, 33 The genomic regions of exon 4 of the IDH1/2 genes were analyzed in two sets using primers and PCR as described. 19, 24 Purified PCR fragments were directly sequenced or were screened for mutations by using denaturing high-performance liquid chromatography. All mutations were confirmed in an independent second experiment by direct sequencing. A total of 122 samples were analyzed by two independent laboratories and showed identical results. Mutation analysis for NPM1 exon 12 and for FLT3-ITD was performed as described. 7, 34 Gene expression profiling 36 All P-values were corrected for multiple testing according to the false discovery rate procedure as developed by Benjaminin and Hochberg using Bioconductor package Multtest. 36 
Quantitative RT-PCR
Expression levels of selected genes (KYNU, S100A8 and S100A9) were validated using quantitative RT-PCR. Transcript levels were measured in duplicates based upon the intercalation of SYBRgreen (Finnzymes Inc, Woburn, MA, USA) in an ABI-PRISM-7900HT system (Applied Biosystems, Darmstadt, Germany), and calculated relative to glyceraldehyde-3-phosphate dehydrogenase expression.
Statistical analysis
Event-free survival (EFS) was defined as the time from diagnosis to the date of last follow-up in complete remission or first event. Events were resistance to therapy (non-response), relapse, secondary neoplasm or death from any cause. Failure to achieve remission due to early death or non-response was considered as events at time zero. Overall survival (OS) was defined as the time of diagnosis to death from any cause or last follow-up. The Kaplan-Meier method was used to estimate survival rates, differences were compared with the two-sided log-rank test. The Cox proportional hazards model was used for uni-and multivariate analyses. Cumulative incidence (CI) functions for competing events were constructed by the method of Kalbfleisch and Prentice, and were compared with the Gray's test. Results are presented as estimated probability of 5-years EFS and estimated cumulative incidence of relapse with standard error (±s.e.). Differences in the distribution of individual parameters among patient subsets were analyzed using the Fisher's exact test for categorized variables and the MannWhitney-U test for continuous variables. All statistical analyses were conducted using the SAS program (SAS-PC, Version 9.1; SAS Institute Inc., Cary, NC, USA).
Results
Patient population
Mutations in IDH1 and IDH2 were analyzed in pretreatment samples from 460 newly diagnosed AML patients. Comparison of clinical characteristics and outcome for the tested population vs the population included in the different treatment protocols revealed no significant differences in induction CR rates, OS or EFS from study entry. Higher diagnostic white blood cell counts (Po0.001) were observed in the tested population as compared with the whole population, whereby those tested were older (Po0.001). In addition, the tested population included fewer patients with megakaryocytic leukemia (P ¼ 0.002).
Incidence of IDH1 and IDH2 mutations in AML patients IDH1 and IDH2 mutations were found in 18 out of 459 (4%; 95% CI±1.8%) pediatric patients with AML. Eight heterozygous point mutations were detected in exon 4 of IDH1, all affecting codon 132. Although a conversion of CGT4TGT leading to a R132C substitution and a conversion of CGT4CAT leading to a R132H were detected in three cases each, the conversion of a CGT4GGT leading to a R132G substitution was observed in two patients. Eight out of the ten patients with IDH2 mutations showed a conversion of CGG4CAG leading to a R140Q substitution. One patient harbored a CGG4CTG change resulting in a R140L substitution and one patient had a conversion of CGG4TGG resulting in a R140W substitution. No mutations affecting codon R172 of IDH2 were detected. Furthermore, one missense mutation in codon 116 (AAT4AGT) of IDH1, causing the substitution of the amino acid asparagine by serine, was found. Using Polyphen-2 prediction software, 37 the alteration is located in a highly conserved site and is scored as probably damaging. Unfortunately, no germline material was available to test the leukemic-specific origin of this mutation. However, neither this mutation nor the affected codon has been described before. Therefore, we regarded this mutation as an unclassified variant and we excluded this case for all survival analyses. In this cohort, mutations in IDH1 and IDH2 were mutually exclusive.
Correlation of IDH1/2 mutations and IDH SNP rs11554137 with clinical features, biological characteristics and other gene mutations
As both IDH1 and IDH2 mutants cause the loss of the physiologic enzyme function resulting in elevated 2-hydroxyglutarate levels, 13, 14, 38 all statistical analyses on prevalence and prognostic influence were performed with the combined mutation status of IDH1 and IDH2. Additionally, a second analysis in which IDH1 and IDH2 mutations were each analyzed separately for impact on OS and EFS can be found in the supplement (Supplementary Figure S1 ).
There were no significant differences between IDH mutated and IDH wildtype patients with respect to sex, cytogenetic risk group, central nervous system involvement, hemoglobin levels, white blood cell count, platelet count or blast count. However, IDH mutations were significantly associated with an intermediate age (2-10 years; 79 vs 33% in other patients, P ¼ 0.008) and with FAB M1/M2 (71 vs 39%, P ¼ 0.013).
A t(8;21) or a t(15;17) was diagnosed in three and two patients, respectively. Five of the 14 IDH mutated patients with available cytogenetics had a normal karyotype (35.7%). IDH1/2 mutations were significantly more often in patients with concomitant NPM1 mutations (39 vs 10%; P ¼ 0.001). Other co-occurring mutations were partial tandem duplications in the MLL gene in three patients and a CEBPA double mutation in one patient. The main biological and clinical features of the 18 IDH mutated patients are summarized in Table 1 .
In the present pediatric cohort, the minor allele of SNP rs11554137 (SNP þ ) was detected in 47 out of 460 patients (10.2%; 95% CI ± 2.8%). Thus, its prevalence in the pediatric patients was comparable to adult AML patients (10.9%) and adult controls (12%). 24 All baseline characteristics, cytogenetic aberrations and gene mutations were similarly distributed between SNP þ and SNPÀ patients.
Influence of IDH1/2 mutations and IDH SNP rs11554137 on treatment response and survival A total of 17 patients (94%) with IDH1/2 mutations achieved a CR compared with 387 IDH1/2 wildtype patients (88%; P ¼ 0.52). In univariate analysis, IDH mutated patients compared with IDH wildtype patients had a significantly superior OS while no statistical difference was observed for EFS (OS: P ¼ 0.032; EFS: P ¼ 0.14; Figures 1a and b) . This was also true when looking at the risk defined subgroups (data not shown). No difference in achievement of CR (P ¼ 0.754) was observed between IDH SNP þ and IDH SNPÀ patients. In univariate analysis, SNP þ patients showed no difference for outcome parameters (OS: P ¼ 0.62; EFS: P ¼ 0.27). A multivariate analysis for OS considering IDH mutations status, cytogenetic risk group, white blood cell count and NPM1 mutation status revealed no independent prognostic significance for the IDH mutation status (HR ¼ 0.49, CI 95% 0.07-3.6, P ¼ 0.484; Table 2 ).
Gene expression profiling of IDH mutated cases
We compared the gene expression profiles of IDH mutated cases (n ¼ 12) with other AML cases (n ¼ 201), and identified 18 significantly differentially expressed probe sets (false discovery rate-adjusted Po0.05; Supplementary Table S1). These included three probe sets annotating the PAWR gene (PRKC, apoptosis, WT1, regulator protein), showing upregulated Table S2 ). Validation with quantitative RT-PCR correlated with micro-array expression values, and showed downregulated expression of S100A8 and S100A9 in IDH mutated cases (Figures  2a and b) . Pathway analysis on Kyoto Encyclopedia of Genes and Genomes-based gene sets revealed the tryptophan metabolism as the only significantly enriched Kyoto Encyclopedia of Genes and Genomes-pathway (false discovery rate-adjusted P-value o0.05). Deregulation of this process in IDH mutated cases was sustained by a pathway analysis using Gene Ontology terms, which showed 25 significantly discriminative Gene Ontology terms, among which the tryptophan metabolism was clearly enriched (Supplementary Table S3 ). The expression of KYNU encoding the enzyme kynureninase, involved in this pathway, was validated by quantitative RT-PCR, and indeed showed a significantly downregulated expression in IDH mutated cases (Figure 2c ).
Discussion
In this large cohort of pediatric patients with AML, mutations in the IDH1 and IDH2 genes were identified as recurrent mutations in childhood AML. With a frequency of 4% in pediatric AML patients, mutations in the IDH genes are substantially less frequent in pediatric as compared with adult AML patients, where the prevalence is up to 33%. 20 The lower frequency of IDH1 mutations is in accordance to a recent Italian study that found IDH1 mutations in 2.4% of childhood AML cases. 26 In pediatric AML, mutations in codon R140 of IDH2 have only been described in a single case 27 and our findings outline that they have a similar frequency to IDH1 in that age group. Interestingly, we did not find any mutations affecting codon R172 of IDH2 in patients with childhood AML. This finding appears to be in line with previous studies in adult AML where 77% of patients with R172 IDH2 mutations were elderly patients (X60 years of age). 20 In the present study, we identified a strong association between NPM1 and IDH mutations that was already described for adult AML patients. 20, 24, 39, 40 Similar to our findings for IDH mutations, mutations in NPM1 also occur less frequently in pediatric AML patients compared with adult 7 However, in contrast to adult AML, IDH mutations were not associated with a normal karyotype in childhood AML. Interestingly, these mutations were also recurrently observed in patients with good-risk cytogenetics (three patients with t(8;21), two patients with t (15;17)). Both types of IDH mutations did not occur in children o3 years which affirms the distinctiveness of infant AML.
The prognostic effect of IDH mutations in adult AML has been intensively studied but remains a matter of discussion. Although some studies have suggested a negative prognostic effect for different subgroups of cytogenetically normal AML patients, 18, [20] [21] [22] [23] others have not found any prognostic effect. 19, 24, 25, 37 Little is known about the prognostic effect of IDH mutations in childhood AML. Interestingly, we found a positive prognostic impact of the mutations in childhood for OS (P ¼ 0.032). In this line, all IDH mutated patients who relapsed are now in complete remission after stem cell transplantation. A multivariate analysis for OS revealed that the IDH mutation status did not add new independent prognostic information to the established stratification system. The prognostic evaluation of the mutation is certainly limited by the low number of mutated patients and further studies are needed to complement the prognostic assessment. However, the data clearly point in a different prognostic direction compared with adult AML. Another important difference may be the considerably higher proportion of patients presenting with favorable cytogenetics as compared with adult patients, with more than one third of IDH mutated children presenting with t(8;21) and t (15;17) . In adult AML, the occurrence of IDH1/2 mutations in favorable risk patients has been observed only occasionally (o1%). 23, 41 In line with our results is a recently reported pediatric AML patient with IDH2 R140Q mutation who presented with a t(8;21) together with complex chromosomal aberrations. In addition it has to be kept in mind that dose intensity of induction chemotherapy in pediatric protocols exceeds those in adult studies significantly. Thus, although not formally proven, these two factors might be relevant for the profound differences in the prognostic implications of IDH mutations.
We also found a difference between adult and childhood AML when analyzing the prognostic impact of the minor allele of SNP rs11554137 located in exon 4 of IDH1. In adult cytogenetically normal AML patients, this SNP was reported to be associated with poor prognosis. 24 Surprisingly, in the present pediatric cohort SNP þ patients did not show any difference for EFS or OS (Figures 1c and d) .
In order to gain biological insight into the contribution of IDH1/2 mutations to leukemogenesis and their potential role in drug response in childhood AML, we compared the gene expression profiles of IDH1/2-mutated AML with other pediatric AML cases. Only 18 discriminative probe sets were identified for IDH mutated cases, indicating that these mutations do not drive a strong specific gene expression profile. This could be caused by a stronger profile of the underlying genetic subtypes, although correcting this did not generate more discriminative genes (data not shown). Moreover, cases in the IDH wildtype group harboring TET2 mutations, which were recently shown to generate similar effects as IDH1/2 mutations in AML, might resemble the IDH mutated profile. 16 However, we did observe an affected tryptophan metabolism, and validated downregulated expression of the enzyme kynureninase, which is involved in the biosynthesis of NAD cofactors from tryptophan. The implication of this altered tryptophan metabolism in IDH mutated AML remains to be elucidated. Furthermore, downregulation of the calcium-binding proteins S100A8 and S100A9 was observed in IDH mutated cases. A recent study reported that high expression of S100A8 in AML correlated with poor outcome, 42 which is in concordance with our data showing downregulated S100A8 and S100A9 expression in combination with a favorable outcome in IDH1/2-mutants. Interestingly, overexpression of S100A8 and S100A9 induces prednisone resistance in pediatric ALL, which might also apply for the well-known steroid resistance in AML. 43, 44 However, further functional studies have to be done to shed more light on the possible role of these genes in IDH mutated AML. In summary, we identified IDH1 and IDH2 mutations as a recurrent but infrequent event in childhood AML. The IDH1/2 mutation status was not associated with independent prognostic significance. These results further underline the differences in the prevalence and also prognostic importance of molecular aberrations between childhood and adult AML.
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